Treatment of chronic myeloid leukemia with autologous
transplantation using peripheral blood stem cells or bone
marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha
administration.

J 2003

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.

HÁJEK, Roman, D. ŽÁČKOVÁ, Tomáš BÜCHLER, Miroslav PENKA, E. KRAHULCOVÁ et. al.

Basic information

Original name

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.

Name in Czech

Léčba chronické myeloidní leukemie autologní transplantací za použití kmenových buněk periferní krve nebo buněk z kostní dřeně kultivovaných s IL-2, GM-CSF a INF alfa.

Authors

HÁJEK, Roman (203 Czech Republic, guarantor), D. ŽÁČKOVÁ (203 Czech Republic), Tomáš BÜCHLER (703 Slovakia), Miroslav PENKA (203 Czech Republic), E. KRAHULCOVÁ (203 Czech Republic), Zdeněk KOŘÍSTEK (203 Czech Republic), J. VINKLÁRKOVÁ (203 Czech Republic), J. ADLER (203 Czech Republic), E. JANOVSKÁ (203 Czech Republic), Karel INDRÁK (203 Czech Republic), E. FABER (203 Czech Republic), M. DOUBEK (203 Czech Republic), M. KLABUSAY (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic), Petr KUGLÍK (203 Czech Republic), L. BOURKOVÁ (203 Czech Republic), L. DUŠEK (203 Czech Republic), Iveta MARESCHOVÁ (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Jiří VORLÍČEK (203 Czech Republic)

Edition

Medical oncology, United States, Humana Press Inc., 2003, 1357-0560

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.159

Organization unit

Faculty of Medicine

UT WoS

000181682400011

Keywords (in Czech)

chronická myeloidní leukemie; autologní transplantace; kmenové buňky

Keywords in English

chronic myeloid leukemia; autologous transplantation; IL-2; GM-CSF; INF alpha; stem cells

Abstract

ORIG CZ

V originále

Interleukin-2 (IL-2) is able to generate nonspecific cytotoxic effectors from hematopoietic precursors. We evaluated the feasibility and efficacy of chronic myeloid leukemia (CML) treatment with autologous hematopoietic stem cell transplantation (HSCT) using grafts cultured in IL-2 followed by immunotherapy with IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon (IFN)-alpha. Eight patients with CML were enrolled: five in an accelerated phase and three in a chronic phase. They received peripheral blood stem cells (PBSC) or bone marrow (BM) cultured in a medium containing IL-2 for 24 h. A median of 1.29 x 10(6) CD34+ cells/kg were infused after conditioning with busulfan (12 16 mg/kg) in PBSC recipients. BM was infused without prior myeloablative therapy. The engraftment occurred with a median of 15 d. Engraftment failure developed in one patient. The transplantation was followed by a 1-mo regimen of IL-2 (0.5 x 10(6) IU/m(2) daily) and GM-CSF, and 6 mo of IFN-alpha. One complete and one transient minor cytogenetic remission were observed. At 24 mo after transplantation, two patients had died of progressive disease and one of infection. Five patients had stable disease in the chronic phase. Autologous transplantation using IL-2-activated graft is feasible and the subsequent IL-2, GM-CSF, and IFN-alpha administration has acceptable toxicity. However, no benefits in comparison with conventional autologous transplantation for CML were identified in our study.

In Czech

Byla vyhodnocena realizovatelnost a efektivita léčby CML autologní transplantací kmenových buněk.

Citovat

HÁJEK, Roman, D. ŽÁČKOVÁ, Tomáš BÜCHLER, Miroslav PENKA, E. KRAHULCOVÁ, Zdeněk KOŘÍSTEK, J. VINKLÁRKOVÁ, J. ADLER, E. JANOVSKÁ, Karel INDRÁK, E. FABER, M. DOUBEK, M. KLABUSAY, Alexandra OLTOVÁ, Petr KUGLÍK, L. BOURKOVÁ, L. DUŠEK, Iveta MARESCHOVÁ, Jiří MAYER and Jiří VORLÍČEK. Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration. Medical oncology. United States: Humana Press Inc.,, 2003, vol. 20, No 1, p. 69-76. ISSN 1357-0560.

@article{838027,
   author = {Hájek, Roman and Žáčková, D. and Büchler, Tomáš and Penka, Miroslav and Krahulcová, E. and Kořístek, Zdeněk and Vinklárková, J. and Adler, J. and Janovská, E. and Indrák, Karel and Faber, E. and Doubek, M. and Klabusay, M. and Oltová, Alexandra and Kuglík, Petr and Bourková, L. and Dušek, L. and Mareschová, Iveta and Mayer, Jiří and Vorlíček, Jiří},
   article_location = {United States},
   article_number = {1},
   keywords = {chronic myeloid leukemia; autologous transplantation; IL-2; GM-CSF; INF alpha; stem cells},
   language = {eng},
   issn = {1357-0560},
   journal = {Medical oncology},
   title = {Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.},
   volume = {20},
   year = {2003}
}

TY  - JOUR
ID  - 838027
AU  - Hájek, Roman - Žáčková, D. - Büchler, Tomáš - Penka, Miroslav - Krahulcová, E. - Kořístek, Zdeněk - Vinklárková, J. - Adler, J. - Janovská, E. - Indrák, Karel - Faber, E. - Doubek, M. - Klabusay, M. - Oltová, Alexandra - Kuglík, Petr - Bourková, L. - Dušek, L. - Mareschová, Iveta - Mayer, Jiří - Vorlíček, Jiří
PY  - 2003
TI  - Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.
JF  - Medical oncology
VL  - 20
IS  - 1
SP  - 69-76
EP  - 69-76
PB  - Humana Press Inc.,
SN  - 13570560
KW  - chronic myeloid leukemia
KW  - autologous transplantation
KW  - IL-2
KW  - GM-CSF
KW  - INF alpha
KW  - stem cells
N2  - Interleukin-2 (IL-2) is able to generate nonspecific cytotoxic effectors from hematopoietic precursors. We evaluated the feasibility and efficacy of chronic myeloid leukemia (CML) treatment with autologous hematopoietic stem cell transplantation (HSCT) using grafts cultured in IL-2 followed by immunotherapy with IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon (IFN)-alpha. Eight patients with CML were enrolled: five in an accelerated phase and three in a chronic phase. They received peripheral blood stem cells (PBSC) or bone marrow (BM) cultured in a medium containing IL-2 for 24 h. A median of 1.29 x 10(6) CD34+ cells/kg were infused after conditioning with busulfan (12 16 mg/kg) in PBSC recipients. BM was infused without prior myeloablative therapy. The engraftment occurred with a median of 15 d. Engraftment failure developed in one patient. The transplantation was followed by a 1-mo regimen of IL-2 (0.5 x 10(6) IU/m(2) daily) and GM-CSF, and 6 mo of IFN-alpha. One complete and one transient minor cytogenetic remission were observed. At 24 mo after transplantation, two patients had died of progressive disease and one of infection. Five patients had stable disease in the chronic phase. Autologous transplantation using IL-2-activated graft is feasible and the subsequent IL-2, GM-CSF, and IFN-alpha administration has acceptable toxicity. However, no benefits in comparison with conventional autologous transplantation for CML were identified in our study.
ER  -

HÁJEK, Roman, D. ŽÁČKOVÁ, Tomáš BÜCHLER, Miroslav PENKA, E. KRAHULCOVÁ, Zdeněk KOŘÍSTEK, J. VINKLÁRKOVÁ, J. ADLER, E. JANOVSKÁ, Karel INDRÁK, E. FABER, M. DOUBEK, M. KLABUSAY, Alexandra OLTOVÁ, Petr KUGLÍK, L. BOURKOVÁ, L. DUŠEK, Iveta MARESCHOVÁ, Jiří MAYER and Jiří VORLÍČEK. Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration. \textit{Medical oncology}. United States: Humana Press Inc.,, 2003, vol.~20, No~1, p.~69-76. ISSN~1357-0560.

Detailed Information on Publication Record